NICE has Gilenya appraisal 'very wrong', says Novartis
This article was originally published in Scrip
NICE has got its preliminary draft recommendations rejecting Novartis's Gilenya (fingolimod) for treating relapsing-remitting multiple sclerosis (RRMS) "very wrong," says the company. The health technology appraisal institute for England and Wales said no to Gilenya, the first pill for treating MS, because of doubts about its relative effectiveness and said that Novartis used the wrong comparators in its submission. But Novartis argues that its choice of comparative treatments was fully aligned with prevailing clinical guidelines, and that NICE’s recommendation denies patient access to a disease-modifying drug. Furthermore, the company maintains that NICE has chosen to ignore significant parts of the information supplied to it by Novartis.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.